nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—SLC22A2—Cytarabine—lymphatic system cancer	0.281	0.375	CbGbCtD
Procainamide—SLC22A1—Cytarabine—lymphatic system cancer	0.244	0.325	CbGbCtD
Procainamide—SLC22A3—Vincristine—lymphatic system cancer	0.225	0.3	CbGbCtD
Procainamide—Electrocardiogram change—Teniposide—lymphatic system cancer	0.0148	0.0634	CcSEcCtD
Procainamide—Hypotensive—Teniposide—lymphatic system cancer	0.0116	0.0496	CcSEcCtD
Procainamide—Sunitinib—ALK—lymphatic system cancer	0.0103	1	CrCbGaD
Procainamide—DNMT1—Vinblastine—Vincristine—lymphatic system cancer	0.00657	1	CbGdCrCtD
Procainamide—Oliguria—Mechlorethamine—lymphatic system cancer	0.00623	0.0266	CcSEcCtD
Procainamide—Supraventricular tachycardia—Fludarabine—lymphatic system cancer	0.00568	0.0243	CcSEcCtD
Procainamide—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.00462	0.0197	CcSEcCtD
Procainamide—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0034	0.0146	CcSEcCtD
Procainamide—Depression—Mechlorethamine—lymphatic system cancer	0.0032	0.0137	CcSEcCtD
Procainamide—Hepatic failure—Fludarabine—lymphatic system cancer	0.003	0.0129	CcSEcCtD
Procainamide—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.003	0.0128	CcSEcCtD
Procainamide—Cardiac failure—Fludarabine—lymphatic system cancer	0.00277	0.0118	CcSEcCtD
Procainamide—Pericarditis—Methotrexate—lymphatic system cancer	0.00255	0.0109	CcSEcCtD
Procainamide—Neutropenia—Teniposide—lymphatic system cancer	0.00248	0.0106	CcSEcCtD
Procainamide—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.00234	0.01	CcSEcCtD
Procainamide—Neutropenia—Fludarabine—lymphatic system cancer	0.00218	0.00934	CcSEcCtD
Procainamide—Renal failure—Fludarabine—lymphatic system cancer	0.00205	0.00875	CcSEcCtD
Procainamide—Arthritis—Bleomycin—lymphatic system cancer	0.00204	0.00871	CcSEcCtD
Procainamide—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00201	0.00858	CcSEcCtD
Procainamide—Flushing—Teniposide—lymphatic system cancer	0.00197	0.00844	CcSEcCtD
Procainamide—Anorexia—Mechlorethamine—lymphatic system cancer	0.00195	0.00835	CcSEcCtD
Procainamide—Chills—Teniposide—lymphatic system cancer	0.00191	0.00816	CcSEcCtD
Procainamide—Hepatic failure—Vincristine—lymphatic system cancer	0.00184	0.00785	CcSEcCtD
Procainamide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00178	0.00762	CcSEcCtD
Procainamide—Chills—Fludarabine—lymphatic system cancer	0.00168	0.00717	CcSEcCtD
Procainamide—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00165	0.00704	CcSEcCtD
Procainamide—Cardiac arrest—Vincristine—lymphatic system cancer	0.00157	0.00671	CcSEcCtD
Procainamide—Confusional state—Teniposide—lymphatic system cancer	0.00152	0.00651	CcSEcCtD
Procainamide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00151	0.00646	CcSEcCtD
Procainamide—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00151	0.00645	CcSEcCtD
Procainamide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00148	0.00632	CcSEcCtD
Procainamide—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00147	0.00628	CcSEcCtD
Procainamide—Malaise—Fludarabine—lymphatic system cancer	0.00147	0.00627	CcSEcCtD
Procainamide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00145	0.0062	CcSEcCtD
Procainamide—Pleural effusion—Methotrexate—lymphatic system cancer	0.00144	0.00616	CcSEcCtD
Procainamide—Anorexia—Teniposide—lymphatic system cancer	0.00144	0.00616	CcSEcCtD
Procainamide—Hypotension—Teniposide—lymphatic system cancer	0.00141	0.00604	CcSEcCtD
Procainamide—Convulsion—Fludarabine—lymphatic system cancer	0.00141	0.00603	CcSEcCtD
Procainamide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0014	0.00599	CcSEcCtD
Procainamide—Neutropenia—Carmustine—lymphatic system cancer	0.0014	0.00597	CcSEcCtD
Procainamide—Myalgia—Fludarabine—lymphatic system cancer	0.00138	0.00592	CcSEcCtD
Procainamide—Arthralgia—Fludarabine—lymphatic system cancer	0.00138	0.00592	CcSEcCtD
Procainamide—Discomfort—Fludarabine—lymphatic system cancer	0.00137	0.00585	CcSEcCtD
Procainamide—Confusional state—Fludarabine—lymphatic system cancer	0.00134	0.00572	CcSEcCtD
Procainamide—Neutropenia—Vincristine—lymphatic system cancer	0.00133	0.0057	CcSEcCtD
Procainamide—Depression—Carmustine—lymphatic system cancer	0.00133	0.00568	CcSEcCtD
Procainamide—Decreased appetite—Teniposide—lymphatic system cancer	0.00131	0.00562	CcSEcCtD
Procainamide—Renal failure—Carmustine—lymphatic system cancer	0.00131	0.0056	CcSEcCtD
Procainamide—Vomiting—Mechlorethamine—lymphatic system cancer	0.0013	0.00557	CcSEcCtD
Procainamide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.0013	0.00556	CcSEcCtD
Procainamide—Neutropenia—Mitoxantrone—lymphatic system cancer	0.0013	0.00555	CcSEcCtD
Procainamide—Flushing—Bleomycin—lymphatic system cancer	0.00127	0.00544	CcSEcCtD
Procainamide—Depression—Vincristine—lymphatic system cancer	0.00127	0.00542	CcSEcCtD
Procainamide—Anorexia—Fludarabine—lymphatic system cancer	0.00126	0.00541	CcSEcCtD
Procainamide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00124	0.00532	CcSEcCtD
Procainamide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00123	0.00528	CcSEcCtD
Procainamide—Chills—Bleomycin—lymphatic system cancer	0.00123	0.00526	CcSEcCtD
Procainamide—Renal failure—Mitoxantrone—lymphatic system cancer	0.00122	0.00521	CcSEcCtD
Procainamide—Nausea—Mechlorethamine—lymphatic system cancer	0.00122	0.0052	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00121	0.00517	CcSEcCtD
Procainamide—Urticaria—Teniposide—lymphatic system cancer	0.0012	0.00513	CcSEcCtD
Procainamide—Oliguria—Methotrexate—lymphatic system cancer	0.0012	0.00512	CcSEcCtD
Procainamide—Abdominal pain—Teniposide—lymphatic system cancer	0.00119	0.00511	CcSEcCtD
Procainamide—Body temperature increased—Teniposide—lymphatic system cancer	0.00119	0.00511	CcSEcCtD
Procainamide—Hallucination—Carmustine—lymphatic system cancer	0.00119	0.00509	CcSEcCtD
Procainamide—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00117	0.00499	CcSEcCtD
Procainamide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00116	0.00494	CcSEcCtD
Procainamide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00115	0.00494	CcSEcCtD
Procainamide—Hallucination—Vincristine—lymphatic system cancer	0.00114	0.00486	CcSEcCtD
Procainamide—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00113	0.00484	CcSEcCtD
Procainamide—Vasculitis—Methotrexate—lymphatic system cancer	0.00113	0.00483	CcSEcCtD
Procainamide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00111	0.00476	CcSEcCtD
Procainamide—Flushing—Carmustine—lymphatic system cancer	0.00111	0.00475	CcSEcCtD
Procainamide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00111	0.00473	CcSEcCtD
Procainamide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00109	0.00468	CcSEcCtD
Procainamide—Asthenia—Teniposide—lymphatic system cancer	0.00108	0.00463	CcSEcCtD
Procainamide—Malaise—Bleomycin—lymphatic system cancer	0.00107	0.0046	CcSEcCtD
Procainamide—Pruritus—Teniposide—lymphatic system cancer	0.00107	0.00457	CcSEcCtD
Procainamide—Cardiac disorder—Vincristine—lymphatic system cancer	0.00106	0.00453	CcSEcCtD
Procainamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00105	0.00449	CcSEcCtD
Procainamide—Diarrhoea—Teniposide—lymphatic system cancer	0.00103	0.00442	CcSEcCtD
Procainamide—Myalgia—Bleomycin—lymphatic system cancer	0.00101	0.00434	CcSEcCtD
Procainamide—Discomfort—Bleomycin—lymphatic system cancer	0.001	0.00429	CcSEcCtD
Procainamide—Chills—Mitoxantrone—lymphatic system cancer	0.000997	0.00427	CcSEcCtD
Procainamide—Confusional state—Bleomycin—lymphatic system cancer	0.000981	0.0042	CcSEcCtD
Procainamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000978	0.00418	CcSEcCtD
Procainamide—Vomiting—Teniposide—lymphatic system cancer	0.00096	0.00411	CcSEcCtD
Procainamide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000953	0.00408	CcSEcCtD
Procainamide—Asthenia—Fludarabine—lymphatic system cancer	0.000952	0.00407	CcSEcCtD
Procainamide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000947	0.00405	CcSEcCtD
Procainamide—Pruritus—Fludarabine—lymphatic system cancer	0.000939	0.00402	CcSEcCtD
Procainamide—Anorexia—Bleomycin—lymphatic system cancer	0.000927	0.00397	CcSEcCtD
Procainamide—Hypotension—Bleomycin—lymphatic system cancer	0.000909	0.00389	CcSEcCtD
Procainamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000908	0.00388	CcSEcCtD
Procainamide—Convulsion—Carmustine—lymphatic system cancer	0.000902	0.00386	CcSEcCtD
Procainamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000898	0.00384	CcSEcCtD
Procainamide—Nausea—Teniposide—lymphatic system cancer	0.000897	0.00384	CcSEcCtD
Procainamide—Hepatic failure—Methotrexate—lymphatic system cancer	0.000891	0.00381	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000886	0.00379	CcSEcCtD
Procainamide—Myalgia—Carmustine—lymphatic system cancer	0.000886	0.00379	CcSEcCtD
Procainamide—Malaise—Mitoxantrone—lymphatic system cancer	0.000872	0.00373	CcSEcCtD
Procainamide—Convulsion—Vincristine—lymphatic system cancer	0.000861	0.00368	CcSEcCtD
Procainamide—Confusional state—Carmustine—lymphatic system cancer	0.000856	0.00366	CcSEcCtD
Procainamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.000846	0.00362	CcSEcCtD
Procainamide—Myalgia—Vincristine—lymphatic system cancer	0.000846	0.00362	CcSEcCtD
Procainamide—Vomiting—Fludarabine—lymphatic system cancer	0.000844	0.00361	CcSEcCtD
Procainamide—Convulsion—Mitoxantrone—lymphatic system cancer	0.000838	0.00359	CcSEcCtD
Procainamide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000831	0.00356	CcSEcCtD
Procainamide—Myalgia—Mitoxantrone—lymphatic system cancer	0.000824	0.00352	CcSEcCtD
Procainamide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000824	0.00352	CcSEcCtD
Procainamide—Lethargy—Methotrexate—lymphatic system cancer	0.000817	0.00349	CcSEcCtD
Procainamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.000814	0.00348	CcSEcCtD
Procainamide—Anorexia—Carmustine—lymphatic system cancer	0.000809	0.00346	CcSEcCtD
Procainamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000802	0.00343	CcSEcCtD
Procainamide—Confusional state—Mitoxantrone—lymphatic system cancer	0.000796	0.00341	CcSEcCtD
Procainamide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000794	0.0034	CcSEcCtD
Procainamide—Hypotension—Carmustine—lymphatic system cancer	0.000794	0.0034	CcSEcCtD
Procainamide—Nausea—Fludarabine—lymphatic system cancer	0.000788	0.00337	CcSEcCtD
Procainamide—Shock—Mitoxantrone—lymphatic system cancer	0.000777	0.00332	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000774	0.00331	CcSEcCtD
Procainamide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000773	0.00331	CcSEcCtD
Procainamide—Urticaria—Bleomycin—lymphatic system cancer	0.000773	0.00331	CcSEcCtD
Procainamide—Anorexia—Vincristine—lymphatic system cancer	0.000773	0.00331	CcSEcCtD
Procainamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000769	0.00329	CcSEcCtD
Procainamide—Hypotension—Vincristine—lymphatic system cancer	0.000757	0.00324	CcSEcCtD
Procainamide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000753	0.00322	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000739	0.00316	CcSEcCtD
Procainamide—Decreased appetite—Carmustine—lymphatic system cancer	0.000738	0.00316	CcSEcCtD
Procainamide—Hypotension—Mitoxantrone—lymphatic system cancer	0.000738	0.00316	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000719	0.00308	CcSEcCtD
Procainamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000717	0.00307	CcSEcCtD
Procainamide—Decreased appetite—Vincristine—lymphatic system cancer	0.000705	0.00302	CcSEcCtD
Procainamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.0007	0.00299	CcSEcCtD
Procainamide—Asthenia—Bleomycin—lymphatic system cancer	0.000698	0.00299	CcSEcCtD
Procainamide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000694	0.00297	CcSEcCtD
Procainamide—Pruritus—Bleomycin—lymphatic system cancer	0.000688	0.00294	CcSEcCtD
Procainamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000686	0.00294	CcSEcCtD
Procainamide—Eosinophilia—Methotrexate—lymphatic system cancer	0.000685	0.00293	CcSEcCtD
Procainamide—Body temperature increased—Carmustine—lymphatic system cancer	0.000671	0.00287	CcSEcCtD
Procainamide—Abdominal pain—Carmustine—lymphatic system cancer	0.000671	0.00287	CcSEcCtD
Procainamide—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000663	0.00284	CcSEcCtD
Procainamide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000663	0.00284	CcSEcCtD
Procainamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000651	0.00278	CcSEcCtD
Procainamide—Neutropenia—Methotrexate—lymphatic system cancer	0.000647	0.00277	CcSEcCtD
Procainamide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000646	0.00276	CcSEcCtD
Procainamide—Abdominal pain—Vincristine—lymphatic system cancer	0.000641	0.00274	CcSEcCtD
Procainamide—Body temperature increased—Vincristine—lymphatic system cancer	0.000641	0.00274	CcSEcCtD
Procainamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000627	0.00268	CcSEcCtD
Procainamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000626	0.00268	CcSEcCtD
Procainamide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000624	0.00267	CcSEcCtD
Procainamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000624	0.00267	CcSEcCtD
Procainamide—Vomiting—Bleomycin—lymphatic system cancer	0.000619	0.00265	CcSEcCtD
Procainamide—Depression—Methotrexate—lymphatic system cancer	0.000615	0.00263	CcSEcCtD
Procainamide—Asthenia—Carmustine—lymphatic system cancer	0.000609	0.00261	CcSEcCtD
Procainamide—Renal failure—Methotrexate—lymphatic system cancer	0.000606	0.00259	CcSEcCtD
Procainamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000597	0.00256	CcSEcCtD
Procainamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000582	0.00249	CcSEcCtD
Procainamide—Asthenia—Vincristine—lymphatic system cancer	0.000582	0.00249	CcSEcCtD
Procainamide—Diarrhoea—Carmustine—lymphatic system cancer	0.000581	0.00249	CcSEcCtD
Procainamide—Nausea—Bleomycin—lymphatic system cancer	0.000578	0.00247	CcSEcCtD
Procainamide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000576	0.00246	CcSEcCtD
Procainamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000566	0.00242	CcSEcCtD
Procainamide—Dizziness—Carmustine—lymphatic system cancer	0.000562	0.0024	CcSEcCtD
Procainamide—Diarrhoea—Vincristine—lymphatic system cancer	0.000555	0.00237	CcSEcCtD
Procainamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00054	0.00231	CcSEcCtD
Procainamide—Vomiting—Carmustine—lymphatic system cancer	0.00054	0.00231	CcSEcCtD
Procainamide—Dizziness—Vincristine—lymphatic system cancer	0.000536	0.00229	CcSEcCtD
Procainamide—Vomiting—Vincristine—lymphatic system cancer	0.000515	0.00221	CcSEcCtD
Procainamide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000514	0.0022	CcSEcCtD
Procainamide—Nausea—Carmustine—lymphatic system cancer	0.000504	0.00216	CcSEcCtD
Procainamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000502	0.00215	CcSEcCtD
Procainamide—Chills—Methotrexate—lymphatic system cancer	0.000497	0.00213	CcSEcCtD
Procainamide—Nausea—Vincristine—lymphatic system cancer	0.000482	0.00206	CcSEcCtD
Procainamide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000472	0.00202	CcSEcCtD
Procainamide—Nausea—Mitoxantrone—lymphatic system cancer	0.000469	0.00201	CcSEcCtD
Procainamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000447	0.00191	CcSEcCtD
Procainamide—Malaise—Methotrexate—lymphatic system cancer	0.000435	0.00186	CcSEcCtD
Procainamide—Convulsion—Methotrexate—lymphatic system cancer	0.000418	0.00179	CcSEcCtD
Procainamide—Arthralgia—Methotrexate—lymphatic system cancer	0.00041	0.00176	CcSEcCtD
Procainamide—Myalgia—Methotrexate—lymphatic system cancer	0.00041	0.00176	CcSEcCtD
Procainamide—Discomfort—Methotrexate—lymphatic system cancer	0.000405	0.00173	CcSEcCtD
Procainamide—Confusional state—Methotrexate—lymphatic system cancer	0.000397	0.0017	CcSEcCtD
Procainamide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000385	0.00165	CcSEcCtD
Procainamide—Anorexia—Methotrexate—lymphatic system cancer	0.000375	0.0016	CcSEcCtD
Procainamide—Hypotension—Methotrexate—lymphatic system cancer	0.000368	0.00157	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000358	0.00153	CcSEcCtD
Procainamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000342	0.00146	CcSEcCtD
Procainamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000324	0.00139	CcSEcCtD
Procainamide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000322	0.00138	CcSEcCtD
Procainamide—Urticaria—Methotrexate—lymphatic system cancer	0.000312	0.00134	CcSEcCtD
Procainamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000311	0.00133	CcSEcCtD
Procainamide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000311	0.00133	CcSEcCtD
Procainamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00029	0.00124	CcSEcCtD
Procainamide—Asthenia—Methotrexate—lymphatic system cancer	0.000282	0.00121	CcSEcCtD
Procainamide—Pruritus—Methotrexate—lymphatic system cancer	0.000278	0.00119	CcSEcCtD
Procainamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000269	0.00115	CcSEcCtD
Procainamide—Dizziness—Methotrexate—lymphatic system cancer	0.00026	0.00111	CcSEcCtD
Procainamide—Vomiting—Methotrexate—lymphatic system cancer	0.00025	0.00107	CcSEcCtD
Procainamide—Nausea—Methotrexate—lymphatic system cancer	0.000234	0.001	CcSEcCtD
